CD8A and neoplasm: Another pre-clinical study has demonstrated that the monotherapy of B10G5 (sMIC-neutralizing antibody) or combination with ALT-803 (immunostimulatory IL-15 super-agonist complex) significantly increased the NKG2D + CD8+ T cells and decreased the primary tumor burden and abolished metastasis in mouse-bearing B16-sMICB tumors.